|1.||Jordan, V C: 2 articles (09/2014 - 12/2000)|
|2.||Giustozzi, Giammario: 2 articles (03/2005 - 04/2002)|
|3.||Marinucci, Lorella: 2 articles (03/2005 - 04/2002)|
|4.||Balducci, Chiara: 2 articles (03/2005 - 04/2002)|
|5.||Locci, Paola: 2 articles (03/2005 - 04/2002)|
|6.||Lilli, Cinzia: 2 articles (03/2005 - 04/2002)|
|7.||Cagini, Lucio: 2 articles (03/2005 - 04/2002)|
|8.||Cabot, Myles C: 1 article (09/2015)|
|9.||Morad, Samy A F: 1 article (09/2015)|
|10.||Obiorah, I E: 1 article (09/2014)|
|1.||Breast Neoplasms (Breast Cancer)
09/01/2014 - "Triphenylethylene (TPE)-like compounds were the first agents to be used in the treatment of metastatic breast cancer in postmenopausal women. "
01/01/2012 - "The aim of this work was to develop a novel (99m)Tc-labelled derivative based on triphenylethylene for breast cancer imaging. "
08/01/1990 - "The antitumor activity of the new triphenylethylene drug toremifene has been studied in advanced breast cancer of postmenopausal women as first line treatment at dose levels of 20, 60, and 240 mg, and as second line or later treatment at high dose levels of 200-240 mg. The response rates (complete + partial response) have been 21% with 20 mg (14 patients), 52% with 60 mg (93 patients in three separate trials), and 68% with 240 mg (38 patients) as first line treatment. "
01/01/1997 - "Toremifene (Fareston)-a novel antiestrogenic drug with a triphenylethylene structure-is effective in the treatment of postmenopausal breast cancer patients. "
01/01/1996 - "Toremifene (Fareston)-a novel antiestrogenic drug with a triphenylethylene structure-has been effective in the treatment of postmenopausal breast cancer patients. "
01/01/1994 - "These compounds are able to antagonize the oestrogenic effects of triphenylethylene antioestrogens and especially the growth of resistant mammary tumors stimulated by the latter compounds. "
01/01/1994 - "It is now widely accepted that the oestrogen receptor is the major if not the only mediator of antioestrogenic and antitumoral effects of triphenylethylene antioestrogens in mammary tumor cells. "
01/01/1959 - "[Distribution of radioactivity in mammary, adipose & tumor tissues in the mouse following injection of a synthetic estrogen: radiocarbon-labeled triphenylethylene]."
01/01/2003 - "Tamoxifen, a triphenylethylene antiestrogen, has been shown to be effective in limiting tumor growth, possibly because of inhibition of angiogenesis. "
09/01/2013 - "Design, synthesis, and anti-tumor activities of novel triphenylethylene-coumarin hybrids, and their interactions with Ct-DNA."
12/01/1992 - "Antitumor effect of triphenylethylene derivative (TAT-59) against human breast carcinoma xenografts in nude mice."
12/01/1992 - "The antitumor activity of a newly synthesized triphenylethylene derivative [(E)-4-[1-[4-[2-(dimethylamino)ethoxy-phenyl]-2-(4-isopropyl)phenyl-1- butenyl] phenyl monophosphate] (TAT-59) was investigated against human breast carcinoma xenografts in nude mice with reference to the changes of hormone receptors. "
05/01/1994 - "The triphenylethylene drug tamoxifen is a hepatocarcinogen in rats, has genotoxic potential and may produce carcinoma of the endometrium in humans, while the structurally closely related toremifene has no carcinogenic or genotoxic potential. "
11/01/1995 - "1. This study has two specific aims: (a) to compare the antioestrogenic activity of two steroidal analogues of 17 beta-oestradiol, the 7 alpha-alkylamide, ICI 164,384 and the 7 alpha-alkylsulphinylamide, ICI 182,780, with that of the triphenylethylene-derived compound 4OH-tamoxifen on a pool of human breast cancer cell lines (HBCCL) with a range of hormonal responsiveness and acquired anti-oestrogen resistance and (b) to investigate the ability of such antioestrogens to modulate the potent breast carcinoma growth-stimulatory activity of the 'IGF-I system'. "
09/01/1997 - "The triphenylethylene antiestrogenic agents, tamoxifen (TX) and toremifene (TO), are currently being used for the therapy of estrogen dependent breast carcinomas and for some other estrogen receptor positive tumors. "
|5.||Body Weight (Weight, Body)
|3.||Estrogen Receptor Modulators (Antiestrogen)
|5.||Protein Kinase C
|10.||Insulin-Like Growth Factor I (IGF-1)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)